We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Orphan Drug Act yielded 491 approvals from 1990-2022 — and 73 of these drugs are among the top 200 most profitable in the world, with global sales exceeding $1 billion, a new analysis has determined. Read More
Suzhou Ribo Life Science and Ribocure Pharmaceuticals (Ribo) announced a $2 billion collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). Read More
The Biden Administration has signaled that it wants HHS to begin using the Defense Production Act (DPA) of 1950 to allow the government to invest in domestic manufacturing of essential medicines to shore up the drug supply chain. Read More
While the FDA has signaled concerns that drugs like Ozempic and Wegovy (semaglutide) come with an increased risk of suicidal ideation, a new study in the journal Nature says they don’t. Read More
How the FDA handles internal scientific disagreements and whether scientists have faced retaliation for expressing differing scientific views is the subject of a letter sent by the House Energy and Commerce Committee to the FDA. Read More
Just days after the FTC won a temporary injunction to halt IQVIA’s proposed acquisition of Propel Media’s DeepIntent healthcare advertising business, the companies have mutually agreed to abandon the proposed merger. Read More
The FDA has approved Florida’s plan to import drugs from Canada, making it the first state permitted to do so, after submitting its plan to the FDA in 2020. Read More
In an effort to stay dominant in the burgeoning obesity market and expand in the liver disease space, Novo Nordisk has forged two new research partnerships, each potentially worth up to $532 million. Read More
In a move that sidesteps pharmacy benefit managers, Eli Lilly has launched a direct-to-consumer marketing program that will provide several of the company’s medicines for obesity, migraine, and diabetes at steeply discounted prices, and without the need for a face-to-face doctor visit. Read More